THOMAS GRAVES: Open Payments
NPI 1942729819 · NEWARK, DE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$334 in 16 payments from 11 companies in 2025. Trend: 2023 $281 · 2024 $367 · 2025 $334
Food & beverage: $334
| Company | Payments | Amount |
|---|---|---|
| BioCryst US Sales Co., LLC | 3 | $101 |
| CSL Behring | 2 | $34 |
| GlaxoSmithKline, LLC. | 2 | $33 |
| ARS Pharmaceuticals Operations, Inc. | 2 | $32 |
| AstraZeneca Pharmaceuticals LP | 1 | $25 |
| Genentech USA, Inc. | 1 | $24 |
| Regeneron Healthcare Solutions, Inc. | 1 | $20 |
| Ionis Pharmaceuticals, Inc. | 1 | $17 |
| Amgen Inc. | 1 | $16 |
| Novartis Pharmaceuticals Corporation | 1 | $16 |
Products named: ORLADEYO, NUCALA, NEFFY, AIRSUPRA, Xolair, DUPIXENT, Hizentra, TEZSPIRE.
Industry payments across DE — which companies pay providers there.
